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Rheumatoid arthritis is an autoimmune disease characterized by synovial hyperplasia
and progressive joint destruction. As reported previously, recombinant human
endostatin (rhEndostatin) is associated with inhibition of joint bone destruction present in
rat adjuvant-induced arthritis; however, the effect of rhEndostatin on bone destruction is
not known. This study was designed to assess the inhibitory effect and mechanisms of
rhEndostatin on formation and function of osteoclasts in vitro, and to gain insight into the
mechanism underlying the inhibitory effect of bone destruction. Bone marrow-derived
macrophages isolated from BALB/c mice were stimulated with receptor activator
of NF-κB ligand (RANKL) and macrophage colony-stimulating factor to establish
osteoclast formation. Osteoclast formation was determined by TRAP staining. Cell
viability of BMMs affected by rhEndostatin was determined using a MTT assay.
Bone resorption was examined with a bone resorption pits assay. The expression
of osteoclast-specific markers was analyzed using quantitative real-time PCR. The
related signaling pathways were examined using a Luciferase reporter assay and
western blot analysis. Indeed, rhEndostatin showed a significant reduction in the
number of osteoclast-like cells and early-stage bone resorption. Moreover, molecular
analysis demonstrated that rhEndostatin attenuated RANKL-induced NF-κB signaling
by inhibiting the phosphorylation of IκBα and NF-κB p65 nuclear translocation.
Furthermore, rhEndostatin significantly inhibited the activation of RANKL-dependent
mitogen-activated protein kinases, such as ERK1/2, JNK, and p38. Hence, we
demonstrated for the first time that preventing the formation and function of osteoclasts
is an important anti-bone destruction mechanism of rhEndostatin, which might be useful
in the prevention and treatment of bone destruction in RA.
Keywords: recombinant human endostatin, osteoclast formation, NF-κB, MAPKs, rheumatoid arthritis, bone
destruction
INTRODUCTION
Severe destruction of the adjacent cartilage and bone is the pathologic hallmark of rheumatoid
arthritis (RA), and ultimately affects one’s ability to do physical activities, thereby reducing the
quality of life (Ochi et al., 2007; Wei et al., 2013). It has been shown that osteoclasts play a
critical role in local bone erosion in RA joints (Gravallese, 2002). In RA, numerous multinucleated
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osteoclast-like cells are present at sites of bone erosion, followed
by degradation of the bone matrix (Pettit et al., 2006). In
contrast, it has been demonstrated that bone erosion does not
appear in osteoclast-deficient mice in arthritis models (Pettit
et al., 2001). Moreover, high receptor activator of NF-κB ligand
(RANKL), an essential factor for osteoclast formation, has been
detected specifically in the synovium of RA patients (Lubberts
et al., 2002). Therefore, osteoclasts are considered to be a type
of critical target cell for inhibiting bone erosion in patients
with RA.
Osteoclasts are large, multinucleated cells derived from the
fusion of monocyte-macrophage lineage precursors. Osteoclasts
play a key role in skeletal development and maintenance
(Hayashibara et al., 2007). It has been suggested that osteoclast
precursors differentiate into active osteoclasts in response
to two key factors (macrophage colony-stimulating factor
[M-CSF] and RANKL). M-CSF induces the proliferation
of bone marrow monocytes (BMMs) toward osteoclast
precursors, sustains survival, and up-regulates expression
of RANK, the receptor of RANKL (Suda et al., 2001). RANKL
promotes osteoclast formation from osteoclast precursors in
the presence of M-CSF (Arai et al., 1999; Koga et al., 2004).
Binding of RANKL with its receptor, RANK, can induce the
recruitment of TNF receptor-associated factor 6 (TRAF6),
leading to the activation of NF-kB and mitogen-activated
protein kinase (MAPK) pathways, and the subsequent up-
regulation of transcription factor nuclear factor of activated
T cells 1 (NFATc1) during osteoclastogenesis (Matsumoto
et al., 2000; Wei et al., 2001; Asagiri and Takayanagi, 2007).
NFATc1 then regulates a number of osteoclastogenesis-related
marker genes, such as calcitonin receptor (CTR), matrix
metalloproteinase 9 (MMP9), or cathepsin K, which lead
to the formation of bone resorption pits during osteoclast
differentiation (Takayanagi, 2007; Hwang and Putney, 2012).
Targeted modulation of the NF-κB and MAPK signaling
pathways to alter NFATc1 expression could be potentially
useful in the prevention and treatment of bone erosion
in RA.
Administration of recombinant human endostatin
(rhEndostatin), which has characteristics of the native
endostatin, has been shown to have an arthritis-inhibiting
effect in adjuvant arthritis (Yue et al., 2007; Huang et al.,
2014). A previous study showed that rhEndostatin treatment
markedly suppresses secondary hind paw swelling and the
polyarthritis index, as well as effectively inhibits bone
degradation during adjuvant-induced arthritis (AA) in rats
(Hu et al., 2012), suggesting that rhEndostatin has a strong
protective effect against progression of AA in rats. Because
bone loss in RA is principally caused by increased osteoclast
activity, inhibiting osteoclastogenesis in mature osteoclasts
is a promising approach for the prevention and treatment
of bone resorption-related disorders (Zeng et al., 2016);
however, whether or not rhEndostatin regulates osteoclast
formation and function has not been reported. In this study we
examined the effects of rhEndostatin on osteoclast formation
and function in vitro, then elucidated the underlying molecular
mechanisms.
MATERIALS AND METHODS
Reagents and Antibodies
Fetal bovine serum (FBS) and α-modified essential medium
(α-MEM) were purchased from Invitrogen (Carlsbad, CA, USA).
Recombinant murine RANKL and M-CSF were purchased
from Peprotech (London, UK). A tartrate-resistant acid
phosphatase (TRAP) kit was obtained using a leukocyte
acid phosphatase staining kit (Sigma–Aldrich Co., St. Louis,
MO, USA). Antibodies against the non-phosphorylated and
phosphorylated forms of p65, IκBα, ERK1/2, JNK, and p38 were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA).
Animals and Ethics Approval
Experimental protocols were approved by the Ethics Committee
of Shanghai Medical College of Fudan University (Permit:
20151201-001). All the animal experiments were made to
minimize suffering and reduce the number of animals used. Male
BALB/c mice (11 weeks old) were purchased from the Chinese
Academy of Science (Shanghai, China). These mice were used to
obtain osteoclast precursors from bone marrow cells.
In Vitro Osteoclastogenesis Assay
Mouse bone marrow cells were obtained from male BALB/c
mice (11 weeks old) which were euthanized using sodium
pentobarbital. The tibias and femurs from mice were cut in
half, and flushed with phenol red free α-MEM containing 10%
charcoal-stripped FBS and 30 ng/mL of M-CSF. Cells were
cultured in 25-cm2 tissue culture flasks at 37◦C and 5% CO2.
After 24 h, the non-adherent cells were used as osteoclast
precursors and cultured for 3 days in the presence of M-CSF
(30 ng/mL). After 3 days, the resulting adherent cells were used
as bone marrow macrophages (BMMs). For differentiation into
mature osteoclasts, osteoclast precursors were plated at a density
of 1.5 × 106 cells/well and cultured with M-CSF (30 ng/mL) and
RANKL (100 ng/mL) in 24-well culture plates for 7 days with
media replaced every 2 days (Wu et al., 2012; Baek et al., 2014).
TRAP Staining
After 7 days in culture, the cells were fixed in 3.7% formaldehyde
for 15 min at 4◦C. Samples were stained for TRAP according
to the manufacturer’s instructions. TRAP-positive multinuclear
cells with greater than three nuclei were counted as osteoclasts
under a light microscope.
Cytotoxicity Assay
We detected the cytotoxic effect of rhEndostatin using a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
kit (Beyotime Institute of Biotechnology, China), as previously
described (Zhu et al., 2012).
Pit Formation Assays
To measure resorption, cells were cultured and treated, as
described above. Briefly, BMMs (2 × 105 cells/well) were plated
on bone slices and treated with rhEndostatin (50 mM) in the
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presence of M-CSF (30 ng/mL) and RANKL (100 ng/mL) for
7 days, then removed by sonication and the dentine slices (IDS,
Boldon, UK) was stained with toluidine blue. The resorption
areas were observed under a light microscope and analyzed with
ImageJ software.
Real-Time PCR Analysis
Real-time PCR was used to determine the effects of rhEndostatin
treatment on the level of mRNA expression of RANKL-induced
osteoclast specific genes (NFATc1, CTR, MMP9, and cathepsin
K), as described previously (Zhu et al., 2012; Li et al., 2013).
Gene-specific primers used in PCR are listed in Supplementary
Table S1.
Luciferase Reporter Assay
NF-κB transcriptional activity was measured using a
luciferase reporter assay. Cells were transfected with 1 µg
of pGL4.32[luc2P/NF-κB-RE/Hygro] vector and 1 µg of
pGL4.44[luc2P/AP1 RE/Hygro] vector (Promega, Madison,
WI, USA) using Lipofectamine 2000 (Invitrogen). To detect
luciferase activity, the BMMs were lysed with 1 × passive
lysis buffer (Promega) and the cell lysate was then mixed with
luciferase assay substrate. Luciferase activity was measured
using the dual-luciferase reporter assay system according to the
manufacturer’s instructions (Promega).
Western Blotting
Whole cells were lysed in lysis buffer, supplemented with
protease inhibitor mixture (Roche Applied Science, Indianapolis,
IN, USA). Fractionation of nuclear and cytosolic proteins was
isolated using a Nuclear/Cytosol Fractionation Kit (BioVision,
Inc., Mountain View, CA, USA), according to the manufacturer’s
instructions. The lysates were fractionated on a 10% SDS-PAGE
gel and transferred to PVDF membranes. The membranes were
blocked for 1 h at room temperature with 5% skim milk and
incubated with different antibodies overnight at 4◦C. All of the
primary antibodies were diluted to 1:800. After being rinsed,
the membranes were incubated with secondary antibodies for
1 h at room temperature. The bands were visualized using
film exposure with densitometry (Gel Logic 2200; Rochester,
NY, USA). ImageJ software was used to analyze protein band
intensity.
Statistical Analysis
Data are expressed as the mean ± SEM. Statistical analysis was
performed using SPSS 13.0 software. Statistical differences were
assessed by one-way analysis of variance followed by a post hoc
Tukey’s test. P < 0.05 were accepted as a significant difference.
RESULTS
Effect of rhEndostatin on
Osteoclast-Like Cell Formation
We first compared the inhibitory effects of rhEndostatin on
osteoclast-like cell formation in mouse BMM cultures. Mouse
BMMs were cultured in the presence of M-CSF and RANKL
with increasing concentrations of rhEndostatin (12.5, 25, and
50 mM). As shown in Figure 1A, TRAP-positive multinuclear
osteoclasts from BMMs formed within 3 days in control cultures.
RhEndostatin inhibited osteoclast-like cell formation in a dose-
dependent manner (Figure 1B). RhEndostatin (12.5, 25, and
50 mM) treatments produced a marked suppression of the
number of osteoclasts derived from BMMs in a dose-dependent
manner.
To determine whether or not cytotoxic effects of rhEndostatin
contributed to suppressing osteoclast-like cell formation, we
analyzed the cytotoxicity of rhEndostatin by MTT assay in BMMs
(Figure 1C). rhEndostatin was minimally cytotoxic to BMMs
at concentrations up to 100 µM, suggesting that the effects of
rhEndostatin on osteoclast-like cell formation are not caused by
cytotoxic effects of the compound.
Effects of rhEndostatin on Stages of
Osteoclast-Like Cell Formation
Osteoclast formation requires some processes, including
proliferation, differentiation, cell fusion, and multi-nucleation.
To determine at which stage rhEndostatin inhibited osteoclast
formation, rhEndostatin was added to BMMs (+M-CSF and
RANKL) at different times during a 5-days culture period
(Figure 2A). After exposure to rhEndostatin for 24 h, the
culture media containing the rhEndostatin was washed off and
changed to rhEndostatin-free culture media. The addition of
rhEndostatin on days 0–1 and 1–2 markedly reduced osteoclast-
like cell formation; however, rhEndostatin treatment at later
stages (days 3–5) did not effectively block osteoclast-like cell
formation. Our results demonstrated that rhEndostatin likely
suppress osteoclast-like cell formation by targeting the early
stage of differentiation (Figure 2B).
Effects of rhEndostatin on the Bone
Resorbing Function of Osteoclast-Like
Cell Formation
To determine the functional implications of rhEndostatin
inhibition of cytoskeletal organization, we assessed the capacity
of osteoclast-like cells to resorb a mineralized matrix. BMMs
were plated on bone slices and stimulated with M-CSF and
RANKL for 5 days to generate mature osteoclasts in the
presence or absence of rhEndostatin (12.5, 25, and 50 mM).
As shown in Figure 3A, numerous bone resorption pits were
formed on the dentine slices in control cultures. RhEndostatin
(12.5, 25, and 50 mM) treatment strongly diminished areas
of bone resorption pits resulting from M-CSF and RANKL-
induced BMMs (Figure 3B). These findings demonstrated that
rhEndostatin impaired osteoclast bone resorption in vitro.
Effects of rhEndostatin on the
Expression of Osteoclast-Specific
Markers
During osteoclast formation and bone resorption, the level of
expression of several specific genes, such as NFATc1, CTR,
MMP9, and cathepsin K, are closely related to the eventual
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FIGURE 1 | Effects of rhEndostatin on RANKL-induced osteoclast-like cell formation in mouse BMMs. (A) Mouse BMMs were cultured with vehicle
(distilled water) or the indicated concentrations of rhEndostatin for 3 h, then stimulated with M-CSF (30 ng/mL) and RANKL (100 ng/mL) for 5 days. The osteoclasts
were fixed and stained for TRAP staining. (B) TRAP-positive multi-nucleated cells with greater than three or more nuclei were counted as osteoclasts. (C) Effects of
rhEndostatin on the cell viability of BMMs. BMMs were treated with the indicated concentrations of rhEndostatin for the indicated times. Cell viability was determined
by the MTT method. ∗∗P < 0.01 compared with vehicle-treated control.
formation and function of osteoclasts (Takayanagi, 2007; Hwang
and Putney, 2012). Therefore, in the present study we assessed
the effects of rhEndostatin on the expression of these molecules
in BMMs induced by M-CSF and RANKL. As shown in Figure 4,
mouse BMMs were cultured in the presence of RANKL and
M-CSF led to significant up-regulation of the expression of
NFATc1, CTR, MMP9, and cathepsin K mRNA in control
cultures. Moreover, rhEndostatin treatment dramatically reduced
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FIGURE 2 | Effects of rhEndostatin on osteoclast-like cell formation treated for different time periods. (A) Schematic of the experimental design for the
in vitro experiments. BMMs were cultured in the presence of M-CSF and RANKL for 5 days, and rhEndostatin (50 mM) was added to the BMM cultures at the
indicated days. (B) The number of TRAP-positive multi-nucleated cells were counted. The data are presented as percentages relative to the vehicle-treated control
group. ∗∗P < 0.01 compared with the vehicle-treated control.
the levels of NFATc1, CTR, MMP9, and cathepsin K mRNA
in a concentration-dependent manner. Our results suggested
that rhEndostatin suppresses the formation and function of
osteoclasts by inhibiting the gene expression of osteoclast-specific
markers.
RhEndostatin Inhibited the Activation of
the NF-κB Pathway by Inhibiting IκBα
Phosphorylation and the Translocation of
Cytosolic NF-κB-p65 to the Nucleus
Receptor activator of NF-κB ligand-induced NF-κB is an essential
transcription factor that is vital to osteoclast differentiation.
Mice that lack the NF-κB p50 and p52 subunits fail to
generate mature osteoclasts, which leads to the development
of severe osteopetrosis (Asagiri and Takayanagi, 2007). The
activation of NF-κB is regulated by three major steps, as
follows: IκBα phosphorylation; degradation of IκBα; and
nuclear translocation of the p65 subunit of NF-κB. We
determined whether or not rhEndostatin affects RANKL-
induced NF-κB activation. Osteoclast formation was induced
using BMMs in RANKL in the presence or absence of
rhEndostatin. RANKL-induced NF-κB activation was assessed
using an NF-κB luciferase reporter gene assay. As shown in
Figure 5A, RANKL stimulation dramatically increased NF-κB
activity. Indeed, rhEndostatin attenuated RANKL-induced NF-
κB activity in a dose-dependent manner. The cytosolic level
of phosphorylation of IκBα was detected by western blot,
and we showed that RANKL induced the cytosolic level of
phosphorylation of IκBα reached the maximum level after
5 min, whereas the cytosolic level of phosphorylation of IκBα
was markedly decreased by pre-treatment with rhEndostatin
in BMMs (Figures 5B,C). To determine whether or not
rhEndostatin inhibited RANKL-induced nuclear translocation
of p65, nuclear proteins were extracted at 0, 5, 15, 30,
and 60 min, and western blot analysis was carried out in
BMMs. As shown in Figures 5B,C, treatment with RANKL
significantly increased the nuclear phosphorylation of NF-
κB p65, while rhEndostatin attenuated the RANKL-induced
increase in nuclear NF-κB p65 phosphorylation. In contrast,
p65 in cytoplasmic extracts dramatically increased treatment
by rhEndostatin (Supplementary Figure S1). Thus, these data
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FIGURE 3 | Effects of rhEndostatin on bone resorbing function of osteoclasts of BMMs cells induced by M-CSF and RANKL. (A) BMMs were seeded on
dentine slices and treated with vehicle or rhEndostatin (12.5, 25, and 50 mM) for 3 h, then stimulated with M-CSF and RANKL. After culture for 5 days, the cells were
removed from dentine slices, and the slices were stained with toluidine blue. (B) The total area of resorption pits was measured. ∗∗P < 0.01 compared with the
vehicle-treated control.
indicate that rhEndostatin inhibited RANKL-induced osteoclast
formation by regulating the activation of NF-κB.
RhEndostatin Inhibits the
RANKL-Induced Phosphorylation of
MAPKs
In addition to the NF-κB signaling pathway, activation of
the MAPKs plays an important role in osteoclast formation
(Huang et al., 2006). To evaluate the effects of rhEndostatin on
the MAPKs following stimulation with RANKL in BMMs, we
examined the activation of three well-established MAPK sub-
families (ERK1/2, JNK, and p38 MAPK) by western blot. As
shown in Figures 6A,B, RANKL-induced phosphorylation of
ERK1/2 and JNK reached a maximum at 15 min. Moreover,
RANKL-induced phosphorylation of p38 reached a maximum
at 5 min; treatment of BMMs with 50 mM rhEndostatin
significantly suppressed phosphorylation of ERK, p38, and JNK
(Figures 6A,B). Taken together, our results suggested that
rhEndostatin suppresses osteoclastogenesis by attenuating the
activation of MAPK pathways induced by RANKL.
DISCUSSION
The present study demonstrated that rhEndostatin inhibits
osteoclast-like cell formation and osteoclast differentiation
FIGURE 4 | Effects of rhEndostatin on the expression of
osteoclast-specific markers. BMMs were treated with vehicle or
rhEndostatin (12.5, 25, and 50 mM) for 3 h, then stimulated with M-CSF and
RANKL. After culture for 5 days, total RNA was extracted. Quantitative
real-time qPCR was used to analyze the level of mRNA expression of the
indicated genes. GAPDH was used as a loading control. ∗∗P < 0.01
compared with the vehicle-treated control.
in vitro in the initial stage. At the molecular level, rhEndostatin
inhibited RANKL-induced NF-κB activation by affecting the
phosphorylation and degradation of IκBα and NF-κB p65 nuclear
translocation, as well as activation of the MAPK signaling
pathways.
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FIGURE 5 | Effect of rhEndostatin on RANKL-induced activation of NF-κB in BMMs. (A) BMMs were transiently co-transfected with NF-κB luciferase reporter
gene constructs, then pre-treated with vehicle or the rhEndostatin (12.5, 25, and 50 mM) for 3 h. RANKL was added and cells were incubated for an additional 12 h.
The cells were harvested and the level of NF-κB activation was determined using the luciferase reporter assay system. ∗∗P < 0.01 compared with the vehicle-treated
control (B) BMMs were pre-treated with vehicle or the rhEndostatin (50 mM) for 3 h, then stimulated with RANKL (100 ng/mL) for the indicated times. The cytosolic
level of phosphorylated NF-κB IκBα and the nuclear phosphorylation of p65 levels were determined by western blot analysis. (C) Quantification of phosphorylated
NF-κB IκBα and phosphorylation of p65 protein expression were normalized by total IκBα and p65, respectively. ∗∗P < 0.01 compared with the vehicle-treated
control.
Osteoclasts are unique multinuclear giant cells formed by the
fusion of precursor cells of the monocyte/macrophage lineage (Li
et al., 2013). It is known that M-CSF induces osteoclast precursor
cell proliferation into the osteoclast lineage, whereas RANKL
stimulates subsequent osteoclast precursor differentiation into
osteoclasts (Asagiri and Takayanagi, 2007; Kim et al., 2014).
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FIGURE 6 | Effect of rhEndostatin on RANKL-induced activation of MAPK in BMMs. (A) BMMs were pre-treated with vehicle or rhEndostatin (50 mM) for 3 h,
then stimulated with RANKL (100 ng/mL) for the indicated times. Total protein was extracted and analyzed by western blot analysis using antibodies against
phospho-ERK1/2, ERK1/2, phospho-JNK, JNK, phospho-p38, and p38. (B) Quantification of phosphorylated ERK1/2, p38, and JNK protein expression was
normalized by total ERK1/2, p38, and JNK expression, respectively. ∗∗P < 0.01 compared with the vehicle-treated control.
Osteoclast differentiation from precursors can be induced by the
presence of RANKL, a key regulator of osteoclast formation.
Up-regulation of RANKL expression is produced by fibroblast-
like synoviocytes in RA (Kim et al., 2011). As shown herein,
rhEndostatin significantly reduced the number of TRAP-positive
multinuclear osteoclasts derived from BMMs in the presence
of RANKL and M-CSF, suggesting that rhEndostatin inhibits
osteoclast formation. It is evident that the effect of rhEndostatin is
restricted to the early stage of osteoclastogenesis because delayed
addition of rhEndostatin did not affect osteoclast formation.
It is widely believed that the formation of osteoclastic bone
resorption pits arises in the conjunction area with the process of
osteoclast differentiation (Zou et al., 2007). In the current study,
M-CSF and RANKL stimulation in BMMs led to the formation
of many resorption pits on dentine slices, and rhEndostatin
treatment significantly diminished areas of bone resorption pits
resulting from M-CSF and RANKL-induced BMMs. Moreover,
the expression of osteoclast specific genes, such as NFATc1,
CTR, MMP9, and cathepsin K, was reduced in the presence of
rhEndostatin; however, multinucleated cell activation is required
for the activity of osteoclasts. Thus, cytoskeletal arrangements
can be established for the purpose of adherence to the
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mineralized surface, as can be noted on administration of some
bisphosphonates, such as sodium alendronate, to animals or
on the addition of these bisphosphonates to cultures (Arana-
Chavez and Bradaschia-Correa, 2009). Following treatment with
alendronate, osteoclast precursors are recruited, proliferate, and
undergo differentiation to multinucleated osteoclasts, but do
not undergo activation. For this reason, resorptive activity is
negatively affected (Bradaschia-Correa et al., 2013). Therefore,
a focus area for future research is to determine whether or not
rhEndostatin directly affects the activity of osteoclasts.
As a central mediator of immune and inflammatory responses,
NF-κB activation is also thought to be one of the critical
transcription factors of RANKL-induced osteoclast formation
and bone resorption. Gene knockout studies demonstrate
a key role of NF-κB signaling in osteoclast formation,
including p50 and p52 subunits of NF-κB double-knockout
mice that manifested severe osteopetrosis due to impaired
osteoclast formation (Novack, 2011). The current results
showed that 50 mM rhEndostatin treatment inhibited the
activation of NF-κB by inhibiting the phosphorylation of
IκBα, thereby blocking the nuclear translocation and activation
of the p65 subunit of NF-κB. In particular, there was no
significant difference in cellular proliferation at 25 and 50 mM
rhEndostatin compared with controls. Therefore, 50 mM
rhEndostatin was used for all subsequent experiments in
molecular assays.
Three major subfamilies of MAPKs (ERK1/2, JNK, and
p38) shown to be key regulators of various cellular responses,
including cell migration, apoptosis, differentiation, and
proliferation (Krens et al., 2006). These kinases also play an
important role in the differentiation and activation of osteoclasts
and have been considered as key molecular targets associated with
inflammatory bone destruction in RA (Mbalaviele et al., 2006).
Herein we found that the RANKL-induced phosphorylation of
ERK1/2, JNK, and p38 decreased in response to rhEndostatin
treatment in murine BMMs, suggesting that inhibition of the
MAPK pathway is possible in the inhibitory action of this
agent.
Although the RANKL/RANK axis has undoubtedly been
considered to be an essential factor for osteoclastogenesis that
occurs in the bone remodeling physiologic process, tumor
necrosis family superfamily members are known to influence
osteoclast formation and bone resorption by a RANKL-
independent mechanism (Sabokbar et al., 2015; Yuan et al.,
2015). Further consideration should take into account the fact
that rhEndostatin presents similar effects over pro-inflammatory
cytokines involved in RA pathology in addition to RANKL.
To the best of our knowledge, the current study is the first to
provide evidence that rhEndostatin inhibits osteoclast formation
and bone resorption in vitro. Moreover, we have described the
underlying mechanism of action through which rhEndostatin
negatively regulates osteoclast formation by suppressing NF-
κB and MAPK signaling pathways. These results suggest that
rhEndostatin could be an attractive therapeutic agent for the
treatment of osteoclast formation and bone resorption in the
arthritic joint. Although our data demonstrates that rhEndostatin
inhibits the formation and function of osteoclasts in vitro, further
studies are still warranted to comprehensively explore the role
of endostatin in human osteoclast progenitors and patients
with RAs.
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